OraSure Technologies, Inc. OSUR recently announced the acquisition of Sherlock Biosciences, Inc., a global health company ...

Shares of Assembly Biosciences advanced after the company reported encouraging results from a clinical trial of its treatment for the hepatitis B virus. The stock was up 5.2% at $15.49 in premarket ...

With over 1,100 subjects enrolled across 39 clinical study sites, the company is developing and validating the study.

Pulse Biosciences' Nano-Pulse Stimulation technology has indications in several complex medical disorders. Read why I ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 12.56% ...

Reid Bissonnette, Ph.D, Executive Consultant for Translational Research and Development at Xenetic, discusses extension of ...

Coherus BioSciences is expanding in immunotherapy while managing financial risks. Learn why CHRS stock may benefit from the ...

Cellectar Biosciences Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -89.79%. The profit margin, also known as the revenue ratio or gross profit ...

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced its participation in the 43rd Annual J.P. Morgan ...

Solid Biosciences ended Q3 2024 with $171.1 million in cash, securing operations through 2026. Initial Phase 1/2 trial ...

周五，H.C. Wainwright在Assembly Biosciences (NASDAQ:ASMB)公布一项Phase 1b研究的中期数据后，重申了对该公司的中性评级。这项研究评估了ABI-4334，一种用于慢性乙型肝炎病毒（HBV）感染的衣壳组装调节剂。

Ventyx Biosciences报告季度净亏损3860万美元，现金、现金等价物和可销售证券总额为2.797亿美元。分析师报告显示，Piper Sandler维持对该公司的增持评级，而Oppenheimer尽管降低了目标价，但仍保持优于大市评级。H.C. Wainwright继续对Ventyx Biosciences持中性态度。